III study to assess the efficacy of trametinib in patients with recurrent or progressive low-grade serous ovarian or peritoneal cancer

abstracts

Annals of Oncology

LBA60

Randomized phase II (RP2) study of ATR inhibitor M6620 in combination with gemcitabine versus gemcitabine alone in platinum-resistant high grade serous ovarian cancer (HGSOC)

Background: HGSOCs exhibit genomic instability and high replication stress due to universal loss of the G1/S checkpoint (via TP53 mutations), presence of homologous recombination alterations and induction via amplification of MYC and CCNE1 oncogenes. Based on in vitro and in vivo data, we hypothesized that addition of the selective ATR inhibitor M6620 to gemcitabine (gem) would demonstrate acceptable toxicity and superior efficacy in HGSOC. Methods: We conducted a multicenter, open-label, RP2 study of gem/M6620 versus gem alone (1:1 randomization) in platinum resistant HGSOC. Randomization was stratified based on platinum free interval (PFI), (PFI3 months vs > 3 months). Primary endpoint was progression-free survival (PFS) while secondary endpoints included safety, objective response and clinical benefit rate. Unlimited prior lines but 1 prior regimen in the platinum resistant setting were allowed. Patients (pts) received gem 1000 mg/m2 IV on Days 1 and 8 with or without M6620 210 mg/m2 IV on Days 2 and 9 of a 21-day cycle until disease progression (PD) or intolerable toxicity. Pts on gem alone were allowed to crossover to gem/M6620 only if they developed PD by RECIST. In order to have 80% power to detect improvement of median PFS from 15 weeks with gem to 27.3 weeks with gem/M6620 (hazard ratio (HR) ¼0.55) with a onesided alpha level of 0.1, 64 total pts were required. Results: 70 pts were randomized, 36 to gem and 34 to gem/M6620 arms. Kaplan-Meier estimated median PFS was 14.7 weeks in the gem alone versus 22.9 weeks in the gem/ M6620 arm; gem/M6620 HR was 0.57 (90% CI, 0.33-0.997; 1-sided log-rank test p ¼ 0.047). The benefit of addition of M6620 was observed mainly among pts stratified into the PFI3 months group (HR ¼ 0.31; 90% CI, 0.13-0.77; 1-sided p ¼ 0.013); insignificant PFS difference between the two arms was observed among pts with PFI>3 months (HR ¼ 0.95; 90% CI, 0.46-1.97; 1-sided p ¼ 0.45). No increase in treatmentrelated toxic effects was observed in the gem/M6620 arm. Conclusions: Addition of the ATR inhibitor M6620 to gem in platinum resistant HGSOC met the primary endpoint of this RP2 trial without increasing toxicity. Further evaluation of gem/M6620 in this setting is warranted. Clinical trial identification: NCI CTEP: 9944; NCT02595892. Legal entity responsible for the study: National Cancer Institute (NCI). Funding: National Cancer Institute (NCI). Disclosure: P.A. Konstantinopoulos: Advisory / Consultancy, Research grant / Funding (institution), Advisory Board: AstraZeneca; Advisory / Consultancy, Research grant / Funding (institution), Advisory Board: Merck; Advisory / Consultancy, Research grant / Funding (institution), Advisory Board: Tesaro; Advisory / Consultancy, Advisory Board: Vertex; Advisory / Consultancy, Advisory Board: Pfizer; Research grant / Funding (institution): Eli Lilly. R.T. Penson: Advisory / Consultancy, Advisory Board: AbbVie; Advisory / Consultancy, Research grant / Funding (institution), Advisory Board: AstraZeneca; Advisory / Consultancy, Advisory Board: Clovis; Advisory / Consultancy, Research grant / Funding (institution), Advisory Board: Tesaro; Advisory / Consultancy, Research grant / Funding (institution), Advisory Board: Eisai; Advisory / Consultancy, Research grant / Funding (institution), Advisory Board: Merck & Co; Advisory / Consultancy, Research grant / Funding (institution), Advisory Board: Genentech/Roche; Research grant / Funding (institution): Regeneron; Research grant / Funding (institution): Sanofi Aventis; Advisory / Consultancy, Research grant / Funding (institution), Advisory Board: Vascular Biogenics; Advisory / Consultancy, Advisory Board: Sutro Biopharma; Advisory / Consultancy, Advisory Board: Mersana Therapeutics; Research grant / Funding (institution): Array Biopharma. L.R. Duska: Honoraria (self), Advisory / Consultancy: AstraZeneca; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Genentech/Roche; Research grant / Funding (institution): Cerulean; Research grant / Funding (institution): AbbVie; Research grant / Funding (institution): Tesaro; Research grant / Funding (institution): Pfizer; Research grant / Funding (self), Research grant / Funding (institution): GlaxoSmithKline/Novartis; Research grant / Funding (institution): Morab; Honoraria (self), Research grant / Funding (institution): MorphoTek; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Merck; Research grant / Funding (institution): Aduro BioTech; Research grant / Funding (institution): Syndax; Research grant / Funding (institution): Ludwig; Research grant / Funding (institution): LEAP Therapeutics; Research grant / Funding (institution): Eisai; Research grant / Funding (institution): Lycera; Research grant / Funding (institution): Inovio; Advisory / Consultancy: Cue Biopharma; Research grant / Funding (institution): Advaxis. M.A. Crispens:

Volume 30 | Supplement 5 | October 2019

LBA61

A randomized phase II/III study to assess the efficacy of trametinib in patients with recurrent or progressive low-grade serous ovarian or peritoneal cancer

D.M. Gershenson1, A. Miller2, W. Brady3, J. Paul4, K. Carty4, W. Rodgers5, D. Millan6, R.L. Coleman7, K.N. Moore8, S. Banerjee9, K. Connolly10, A.A. Secord11, D.M. O’Malley12, O. Dorigo13, S. Gaillard14, H. Gabra15, P. Hanjani16, H. Huang2, L. Wenzel17, C. Gourley18 1 Gynecologic Oncology and Reproductive Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA, 2NRG Oncology Statistics and Data Management Center, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA, 3 NRG Oncology Statistics and Data Management Center, Roswell Park Comprehensive Cancer Center, Buffalo, TX, USA, 4Cancer Research UK, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK, 5Pathology, Weill Medical College of Cornell University, New York, NY, USA, 6Pathology, Queen Elizabeth University Hospital, Glasgow, UK, 7Gynecologic Oncology and Reproductive Medicine, The M. D. Anderson Cancer Center, Houston, TX, USA, 8Obstetrics & Gynecology, Stephenson Cancer Center at the University of Oklahoma, Oklahoma City, OK, USA, 9Gynaecology Department, Royal Marsden Hospital NHS Foundation Trust, London, UK, 10Medical Oncology, Edinburgh Cancer Centre, Edinburgh, UK, 11Obstetrics & Gynecology, Duke University, Durham, USA, 12Clinical Research Gynecologic Oncology, The Ohio State University, James Cancer Center, Columbus, OH, USA, 13Obstetrics & Gynecology, Stanford University Emergency Resid, Palo Alto, CA, USA, 14Oncology and Gynecology/Obstetrics, Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, MD, USA, 15Surgery and Cancer, Imperial College London Hammersmith Campus, London, UK, 16Obstetrics & Gynecology, Abington Memorial Hospital, Philadelphia, PA, USA, 17Medicine and Public Health, University of California at Irvine, Irvine, CA, USA, 18Nicola Murray Centre for Ovarian Cancer Research, Edinburgh Cancer Research UK Centre, Edinburgh, UK Background: Low-grade serous carcinoma of the ovary/peritoneum (LGSOC) is a rare subtype, accounting for 5-10% of all serous cancers, and is characterized by alterations in the MAPK pathway, relative chemoresistance, and prolonged overall survival (OS) compared to high-grade serous carcinoma. NRG Oncology in the US and the National Cancer Research Network (NCRN) in the UK collaborated on a phase II/III trial to assess the efficacy of a MEK inhibitor trametinib (TRAM) compared to physician’s choice standard of care (SOC) in recurrent LGSOC. Methods: Patients (pts) were randomized 1:1 to receive either TRAM 2 mg daily or 1 of 5 SOC options (weekly paclitaxel, PLD, topotecan, letrozole, or tamoxifen) until disease progression. Pts who progressed on SOC were allowed to crossover to TRAM. The primary objective tested the progression-free survival (PFS) superiority of TRAM vs SOC. Secondary objectives included toxicity, QoL, and objective response rate (ORR) by RECIST 1.1. Exploratory objectives were OS and PFS and ORR after crossover. PFS and OS curves were estimated using the Kaplan-Meier method and compared by a 1sided, a ¼ 0.025 log-rank test. Results: 260 pts (48.1% had >3 prior lines of therapy) were enrolled between Feb 2014 and Apr 2018. Median follow-up was 31.4 months (mo). PFS was significantly improved for TRAM compared to SOC (median, 13.0 vs 7.2 mo; HR 0.48; 95% CI, 0.36-0.64; P < .0001). ORR was 26.2% for TRAM vs 6.2% for SOC (OR 5.4; 95% CI, 2.39-12.21; P< .0001). Response duration for TRAM was significantly better than for SOC (median, 13.63 mo; 95% CI, 8.08-18.76; vs 5.88 mo; 95% CI, 2.76-12.19). Preliminary analysis of QoL patient reported outcomes shows no significant therapy effects. Main Grade >3 AE in TRAM vs SOC were hematologic toxicity (13.4% vs 9.4%), GI toxicity (27.6% vs 29%), skin toxicity (15% vs 3.9%), and vascular toxicity (18.9% vs 8.6%). Median OS for TRAM vs SOC was 37.0 mo (95% CI, 30.3-NE) vs 29.2 mo (95% CI, 23.5-51.6) (HR 0.75; 95% CI, 0.51-1.11). For 88 pts who crossed over to TRAM, median PFS ¼ 10.8 mo (95% CI, 7.3-12.0), and ORR ¼ 15% (95% CI, 0.070.22). Conclusions: Compared to physician’s choice SOC, TRAM was associated with significantly improved PFS and ORR in women with recurrent LGSOC.

doi:10.1093/annonc/mdz394 | v897

Downloaded from https://academic.oup.com/annonc/article-abstract/30/Supplement_5/mdz394.058/5578173 by guest on 25 October 2019

P.A. Konstantinopoulos1, A.E. Wahner Hendrickson2, R.T. Penson3, A. Doyle4, E.C. Kohn4, L.R. Duska5, M.A. Crispens6, A.B. Olawaiye7, I.S. Winer8, L.M. Barroilhet9, S. Fu10, M.T. McHale11, R.J. Schilder12, A. Farkkila1, J. Curtis1, R. Quinn1, C. Whalen1, G.I. Shapiro13, U.A. Matulonis1 1 Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA, 2Medical Oncology, Mayo Clinic, Rochester, MN, USA, 3Medical Oncology, Massachusetts General Hospital, Boston, MA, USA, 4Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD, USA, 5Gynecologic Oncology, University of Virginia Cancer Center, Charlottesville, VA, USA, 6Gynecologic Oncology, Vanderbilt University/Ingram Cancer Center, Nashville, TN, USA, 7Gynecologic Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA, 8Gynecologic Oncology, Wayne State / Karmanos Cancer Institute, Detroit, MI, USA, 9Gynecologic Oncology, University of Wisconsin Hospital, Madison, WI, USA, 10Department of Investigational Cancer Therapeutics, MD Anderson Cancer Center, Houston, TX, USA, 11Gynecologic Oncology, UC San Diego Moores Cancer Center, San Diego, CA, USA, 12Medical Gynecologic Oncology, Thomas Jefferson University Hospital, Philadelphia, PA, USA, 13Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA

Advisory / Consultancy: AbbVie; Research grant / Funding (institution): AstraZeneca. A.B. Olawaiye: Advisory / Consultancy, Advisory Board: Clovis; Advisory / Consultancy, Advisory Board: Tesaro. M.T. McHale: Advisory / Consultancy: Eisai; Research grant / Funding (institution): Verastem. R.J. Schilder: Advisory / Consultancy, Consultant: Incyte; Advisory / Consultancy, Consultant: Immunogen; Advisory / Consultancy, Consultant: Celsion; Advisory / Consultancy, Consultant: Flatiron. G.I. Shapiro: Advisory / Consultancy, Research grant / Funding (self): Eli Lilly; Advisory / Consultancy, Research grant / Funding (self): Merck KGaA/EMD-Serono; Research grant / Funding (self): Merck; Advisory / Consultancy, Research grant / Funding (self): Sierra Oncology; Advisory / Consultancy, Research grant / Funding (institution): Pfizer; Advisory / Consultancy: G1 Therapeutics; Advisory / Consultancy: Roche; Advisory / Consultancy: Bicycle Therapeutics; Advisory / Consultancy: Fusion Pharmaceuticals; Advisory / Consultancy: Cybrexa Therapeutics; Advisory / Consultancy: Astex; Advisory / Consultancy: Almac; Advisory / Consultancy: Ipsen; Advisory / Consultancy: Bayer; Advisory / Consultancy: Angiex; Advisory / Consultancy: Daiichi Sankyo; Research grant / Funding (institution): Array Biopharma. U.A. Matulonis: Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Myriad Genetics; Advisory / Consultancy: Clovis; Advisory / Consultancy: Merck; Advisory / Consultancy: Eli Lilly; Advisory / Consultancy: Mersana; Advisory / Consultancy: Geneos; Advisory / Consultancy: Fuji Firm; Advisory / Consultancy: Immunogen; Advisory / Consultancy: Cerulean; Advisory / Consultancy: 2X Oncology. All other authors have declared no conflicts of interest.

abstracts Clinical trial identification: NCT02101788. Legal entity responsible for the study: National Cancer Institute (NRG Oncology). Funding: National Cancer Institute (US) and Novartis.

v898 | Gynaecological cancers

LBA62

Efficacy and safety of nivolumab (Nivo) 1 ipilimumab (Ipi) in patients (pts) with recurrent/metastatic (R/M) cervical cancer: Results from CheckMate 358

R.W. Naumann1, A. Oaknin2, T. Meyer3, J.M. Lopez-Picazo4, C. Lao5, Y-J. Bang6, V. Boni7, W.H. Sharfman8, J.C. Park9, L.A. Devriese10, K. Harano11, C.H. Chung12, S.L. Topalian13, K. Zaki14, T. Chen15, J. Gu15, B. Li16, A. Barrows17, A. Horvath18, K.N. Moore19 1 Ob/Gyn, Levine Cancer Institute, Charlotte, NC, USA, 2Medical Oncology, Vall d’Hebron University Hospital, Barcelona, Spain, 3Oncology, UCL Cancer Institute, London, UK, 4 Oncology Department, Clınica Universidad de Navarra, Navarra, Spain, 5Oncology, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA, 6Medical Oncology, Seoul National University Hospital, Seoul, Republic of Korea, 7Oncology, START Madrid CIOCC Hospital Madrid Norte Sanchinarro, Madrid, Spain, 8Medical Oncology, Johns Hopkins Bloomberg-Kimmel Institute for Cancer Immunotherapy and Kimmel Cancer Center, Baltimore, MD, USA, 9Medicine, Massachusetts General Hospital, Boston, MA, USA, 10Cancer Center Medische Oncologie, UMC Utrecht Cancer Center, Medische Oncologie, Utrecht, Netherlands, 11Department of Experimental Therapeutics, National Cancer Center Hospital East, Kashiwa, Japan, 12Head & Neck- Endocrine Oncology Department, H. Lee Moffitt Cancer Center University of South Florida, Tampa, FL, USA, 13Johns Hopkins University School of Medicine, Bloomberg-Kimmel Professor of Cancer Immunotherapy, Baltimore, MD, USA, 14Medical Oncology, University College London Hospital, London, UK, 15Oncology, Bristol-Myers Squibb, Lawrence, GA, USA, 16 Biostatistics, Bristol-Myers Squibb, Princeton, NJ, USA, 17Oncology Clinical Development, Bristol-Myers Squibb, Lawrenceville, GA, USA, 18R&D, Bristol-Myers Squibb, Lawrenceville, GA, USA, 19OKC/Sarah Cannon Research Institute, Stephenson Cancer Center at the University of Oklahoma, Nashville, TN, USA Background: High unmet medical need persists in pts with R/M cervical cancer; median overall survival (OS) is < 17 mo after 1L therapy with few options in 2L. Per current guidelines, pts whose tumors express programmed death ligand 1 (PD-L1) are eligible for pembrolizumab in the 2L setting. CheckMate 358 (NCT02488759) is an ongoing openlabel, multi-cohort, phase I/II study of Nivo þ/- Ipi in virus-associated cancers regardless of PD-L1 expression. Here we report an interim analysis of pts with R/M cervical cancer, with or without prior systemic therapies (PST), receiving Nivo þ Ipi. Methods: Eligible pts had R/M cervical cancer treated with 0-2 PST. Pts were randomized to Nivo 3mg/kg Q2W þ Ipi 1mg/kg Q6W (Combo A), or Nivo 1mg/kg þ Ipi 3mg/ kg Q3W for 4 doses followed by Nivo 240mg Q2W (Combo B), for 24 mo until progression or unacceptable toxicity. Primary endpoint: investigator-assessed objective response rate (ORR) by RECIST 1.1; secondary endpoints: OS, progression-free survival (PFS) and duration of response. Results: Median follow-up was 10.7 mo [Combo A, n ¼ 45] and 13.9 mo [Combo B, n ¼ 46]. ORR was higher in Combo B vs Combo A without PST (46% vs 32%) and with PST (36% vs 23%; Table). Median PFS in Combo A was 13.8 mo (95% CI 2.1, not reached [NR]) in pts without PST and 3.6 mo (1.9, 5.1) in pts with PST. Median PFS in Combo B was 8.5 mo (3.7, NR) without PST and 5.8 mo (3.5, 17.2) with PST. Median OS in Combo A was NR (17.4, NR) in pts without PST and 10.3 mo (7.9, 15.2) in pts with PST. Median OS in Combo B was NR without PST (13.9, NR) and 25.4 mo with PST (17.5, NR). Incidence of all/grade 3–4 treatment-related adverse events (AEs) was 80.0%/28.9% in Combo A and 82.6%/37.0% in Combo B. No new safety signals were identified. Conclusions: These results suggest clinical benefit from two regimens of Nivo þ Ipi in pts with R/M cervical cancer regardless of PD-L1 status. Combo B had notable efficacy in pts with PST. AEs were manageable and consistent with previous reports of Nivo þ Ipi therapy. Clinical trial identification: NCT02488759. Editorial acknowledgement: Writing and editorial assistance was provided by Brooke Middlebrook of Evidence Scientific Solutions Inc, and funded by Bristol-Myers Squibb. Legal entity responsible for the study: Bristol-Myers Squibb, Princeton, NJ, USA. Funding: Bristol-Myers Squibb, Princeton, NJ, USA. Disclosure: R.W. Naumann: Research grant / Funding (institution): Bristol-Myers Squib; Advisory / Consultancy, Research grant / Funding (institution): Merck; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Clovis; Advisory / Consultancy, Speaker Bureau / Expert testimony: Genentech; Advisory / Consultancy: Tesaro; Advisory / Consultancy: Janssen; Advisory / Consultancy, Research grant / Funding (institution): OncoMed; Advisory / Consultancy, Research grant / Funding (institution): SutroBio. A. Oaknin: Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Roche; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: AstraZeneca; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution), Travel / Accommodation / Expenses, grant for VHIO: Pharma Mar; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution), Travel / Accommodation / Expenses, grant for VHIO & VHIR: Clovis Oncology; Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (institution), Travel / Accommodation / Expenses, grant for VHIO: Tesaro; Advisory / Consultancy, Research grant / Funding (institution), grant for VHIO: Immunogen; Advisory / Consultancy: Genmab; Research grant / Funding (institution), VHIR: Abbie Deutchland; Research grant / Funding (institution), VHIO: Ability Pharmaceuticals; Research grant / Funding (institution), VHIO: Advaxis Inc; Research grant / Funding (institution), VHIR: Aeterna Zentaris; Research grant / Funding (institution), VHIR: Amgen SA; Research grant / Funding (institution), VHIO: Aprea Therapeutics AB; Research grant / Funding (institution), VHIO: Eisai Ltd; Research grant / Funding (institution), VHIO: F. Hoffmann - La Roche Ltd. ; Research grant / Funding (institution), VHIO: Regeneron Pharmaceuticals; Research grant / Funding (institution), VHIO: Merck Sharp & Dohme de Espa~ na SA; Research grant / Funding (institution), VHIO: Millennium Pharmaceuticals Inc.. T. Meyer: Advisory / Consultancy: Beigene; Advisory / Consultancy: Merck; Advisory / Consultancy, Research grant / Funding (institution): BTG; Advisory / Consultancy: Eisai; Advisory / Consultancy: Ipsen; Research grant / Funding (institution): Bayer; Travel / Accommodation / Expenses, consultancy: BMS. C. Lao: Research grant / Funding (self), Travel / Accommodation / Expenses: BMS; Research

Volume 30 | Supplement 5 | October 2019

Downloaded from https://academic.oup.com/annonc/article-abstract/30/Supplement_5/mdz394.058/5578173 by guest on 25 October 2019

Disclosure: W. Brady: Full / Part-time employment: Sarah Cannon Development Innovations. R.L. Coleman: Advisory / Consultancy, Leadership role, Research grant / Funding (self), Non-remunerated activity/ies: AbbVie; Honoraria (self), Advisory / Consultancy: aravive; Honoraria (self), Honoraria (institution), Advisory / Consultancy, Research grant / Funding (self), Non-remunerated activity/ies: AstraZeneca; Honoraria (self), Honoraria (institution), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses, Non-remunerated activity/ies: clovis; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self), Research grant / Funding (institution), Travel / Accommodation / Expenses, Non-remunerated activity/ies: Roche Genentech; Honoraria (self), Research grant / Funding (self), Travel / Accommodation / Expenses, Non-remunerated activity/ies: Novartisjavascript:%20create_table_line(’1’,%20new%20Array(’ent’,%20’des’,%20’tor’));; Honoraria (self), Research grant / Funding (institution), Travel / Accommodation / Expenses, Nonremunerated activity/ies: Janssen; Honoraria (self), Research grant / Funding (self), Research grant / Funding (institution), Travel / Accommodation / Expenses, Non-remunerated activity/ies: Merck; Honoraria (self), Advisory / Consultancy, Non-remunerated activity/ies: Immunogen; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Tesaro/GSK; Honoraria (self), Research grant / Funding (institution), Travel / Accommodation / Expenses, Non-remunerated activity/ies: Genmab; Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Gamamab; Honoraria (self), Advisory / Consultancy, Research grant / Funding (self), Research grant / Funding (institution), Travel / Accommodation / Expenses, Non-remunerated activity/ies: Oncomed; Honoraria (self), Advisory / Consultancy: Agenus; Research grant / Funding (self), Research grant / Funding (institution): NCI-SPORE. K.N. Moore: Honoraria (institution), Advisory / Consultancy: Clovis. S. Banerjee: Honoraria (self), Research grant / Funding (institution), Travel / Accommodation / Expenses: AstraZeneca; Honoraria (self), Research grant / Funding (institution), Travel / Accommodation / Expenses: Tesaro; Honoraria (self): Clovis; Honoraria (self): Merck Sereno; Honoraria (self): Seattle Genetics; Honoraria (self), Travel / Accommodation / Expenses: Roche; Honoraria (self): PharmaMar; Research grant / Funding (institution): Janssen Cilag; Honoraria (self), Travel / Accommodation / Expenses: Gamamabs. A.A. Secord: Research grant / Funding (institution): AbbVie, Amgen, Astellas Pharma Inc., AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Clovis, Eisai, Endocyte, Exelixis, Incyte, Merck, PharmaMar, Immutep Ltd, Roche/Genentech, Seattle Genetics, Inc, TapImmune and Tesaro; Honoraria (self): Aravive, AstraZeneca, Clovis, Janssen/ Johnson & Johnson, Merck, Mersana, Oncoquest, Roche/Genentech, and Tesaro . D.M. O’Malley: Honoraria (self), Advisory Board: Genelux; Honoraria (self), Research grant / Funding (institution), Advisory Board: Eisai; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): GOG Foundation; Honoraria (self): NCCN; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Immunogen; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Advisory board, Steering Committee: Clovis; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Advisory board: Abbie, Iovance ; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), US PI/Steering Committee: Novocure; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Advisory board, Steering Committee: Tesaro; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Advisory board, steering Committee: AstraZeneca; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Advisory board, PI, Steering Committee: Agenus; Honoraria (self), Advisory / Consultancy, Advisory board: OncoQuest; Honoraria (self), Advisory / Consultancy, Advisory board: Ambry; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Genentech; Research grant / Funding (institution): Regeneron; Research grant / Funding (institution): AMGEN, BMS; Research grant / Funding (institution): Array Biopharma, inVentiv ; Research grant / Funding (institution): Janssen, Tracon; Research grant / Funding (institution): EMD Serono; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution), Advisory board: Leap Therapeutics. O. Dorigo: Advisory / Consultancy, Speaker Bureau / Expert testimony: Tesaro; Speaker Bureau / Expert testimony: AstraZeneca; Advisory / Consultancy: Clovis; Advisory / Consultancy: Merck. S. Gaillard: Research grant / Funding (institution): Pfizer, Bristol-Myers Squibb, Genentech/Roche, Gradalis, Iovance Biotherapeutics, Merck, PharmaMar, TetraLogic Pharmaceuticals, AbbVie; Advisory / Consultancy: AstraZeneca, Immunogen. C. Gourley: Honoraria (self), Honoraria (institution), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: AstraZeneca; Honoraria (self), Honoraria (institution), Advisory / Consultancy: Roche; Honoraria (self), Honoraria (institution), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: MSD; Honoraria (self), Honoraria (institution), Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Tesaro; Honoraria (self), Honoraria (institution), Advisory / Consultancy, Research grant / Funding (institution): Nucana; Honoraria (self), Honoraria (institution), Advisory / Consultancy, Travel / Accommodation / Expenses: Clovis; Honoraria (self), Honoraria (institution), Advisory / Consultancy, Travel / Accommodation / Expenses: Foundation One; Honoraria (self), Honoraria (institution), Advisory / Consultancy: Sierra Oncology; Honoraria (self), Honoraria (institution), Advisory / Consultancy, Travel / Accommodation / Expenses: Cor2ED; Research grant / Funding (institution): Novartis; Research grant / Funding (institution): Aprea. All other authors have declared no conflicts of interest.

Annals of Oncology